Tien Do
Primary Care · Westminster, CANPI 1508348632
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 328 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$705
- Lilly USA, LLC$624
- Nestle Healthcare Nutrition Inc.$570
- Amgen$533
- Boehringer Ingelheim$490
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,745100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $1,345 |
| AbbVie | 42 | $705 |
| Lilly USA, LLC | 35 | $624 |
| Nestle Healthcare Nutrition Inc. | 36 | $570 |
| Amgen | 18 | $533 |
| Boehringer Ingelheim | 21 | $490 |
| GSK | 23 | $457 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $355 |
| Amarin Pharma, Inc. | 19 | $278 |
| Novo Nordisk | 16 | $256 |
| Aimmune Therapeutics, Inc. | 11 | $246 |
| Regeneron Healthcare Solutions, Inc. | 5 | $166 |
| Vivus LLC | 6 | $128 |
| IBSA Pharma Inc. | 1 | $110 |
| Ironwood Pharmaceuticals, Inc | 4 | $99 |
| Merck | 4 | $92 |
| Exact Sciences | 3 | $60 |
| Bayer | 3 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Biogen | 1 | $27 |
| Hikma Pharmaceuticals USA | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Eisai Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $20 |
| Radius Health, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,759 in reported general payments places this provider in the 95th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 141 | $104,886 |
| FarxigaDapagliflozin Propanediol | 93 | $79,500 |
| TradjentaLinagliptin | 86 | $65,129 |
| VascepaIcosapent Ethyl | 113 | $55,013 |
| JanuviaSitagliptin Phosphate | 54 | $38,119 |
| CreonLipase/Protease/Amylase | 20 | $34,663 |
| ProliaDenosumab | 14 | $23,735 |
| RestasisCyclosporine | 22 | $21,093 |
| Diclofenac Sodium | 23 | $20,878 |
| LinzessLinaclotide | 34 | $20,048 |
| ZenpepLipase/Protease/Amylase | 12 | $18,287 |
| OzempicSemaglutide | 16 | $18,189 |
| EliquisApixaban | 18 | $13,618 |
| Cyclosporine | 28 | $12,140 |
| Icosapent Ethyl | 54 | $11,638 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $490 | $170,015227 claims |
| AstraZenecaFarxiga, Brilinta | $1,345 | $89,474109 claims |
| AbbVieCreon, Restasis, Linzess | $705 | $75,80376 claims |
| MerckJanuvia | $92 | $38,11954 claims |
| AmgenProlia | $533 | $23,73514 claims |
| Aimmune Therapeutics, Inc.Zenpep | $246 | $18,28712 claims |
| Novo NordiskOzempic | $256 | $18,18916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 706 primary care providers in California.
Other primary care in Westminster
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.